Study summary · research use only
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this rat study, the authors characterized the weight-reducing effects of the triple monoamine reuptake inhibitor tesofensine in a diet-induced obesity model, using sibutramine and rimonabant as comparators. Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5 mg/kg, p.o.) resulted in a dose-dependent sustained weight loss of 5.7 and 9.9%, respectively. Sibutramine (7.5 mg/kg) caused a sustained weight loss of 7.6%, whereas rimonabant (10 mg/kg) produced only a transient reduction. All compounds inhibited food intake, with the hypophagic effect of tesofensine described as longer lasting. Unlike tesofensine, pair-fed rats' body weight returned to baseline, which the authors interpret as tesofensine stimulating energy expenditure. Tesofensine and sibutramine reduced abdominal and subcutaneous fat and lowered plasma lipids, and only tesofensine suppressed the plasma insulin response below the paired-feeding level.
Abstract
Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans. The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity. Sibutramine and rimonabant were used as reference comparators. Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively. Sibutramine (7.5mg/kg, p.o.) treatment caused a sustained weight loss of 7.6%, whereas the employed dose of rimonabant (10mg/kg, p.o.) only produced a transient weight reduction. While all compounds exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant. In contrast to tesofensine, the body weight of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure. The differential efficacy on weight reduction was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and subcutaneous fat mass which was paralleled by reduced plasma lipid levels. In an oral glucose tolerance test, only tesofensine significantly suppressed the plasma insulin response below the level that could be obtained by paired feeding, indicating that tesofensine further improved glycemic control. In conclusion, the robust weight loss with long-term tesofensine treatment is likely due to a combined synergistic effect of appetite suppression and increased energy expenditure.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.